Search

Displaying results 5431 - 5440 of 10000 in total
  1. Drug

    Pentetreotide

    go.drugbank.com/drugs/DB12602
    ApprovedWithdrawn

    Pentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.

  2. Drug

    CE-326597

    go.drugbank.com/drugs/DB12694
    Investigational

    CE-326,597 has been used in trials studying the treatment of Obesity.

  3. Drug

    Parethoxycaine

    go.drugbank.com/drugs/DB19380
    ApprovedWithdrawn

    Parethoxycaine is a local anesthetic that was previously approved in the US.

  4. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

    Categories: Serotonin Receptor Antagonists
  5. Drug

    Cathinone

    go.drugbank.com/drugs/DB01560
    ExperimentalIllicit

    Closely related to ephedrine, cathine and other amphetamines, it is probably the main contributor to the stimulant effect of Catha edulis. … Cathinone was added to the Controlled Substances Act's Schedule I in 1993 in compliance with international laws.

  6. Drug

    (Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide

    go.drugbank.com/drugs/DB06941
    Experimental

    This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.

  7. Drug

    4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine

    go.drugbank.com/drugs/DB08667
    Experimental

    This compound belongs to the fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring. This substance targets the protein methionine aminopeptidase.

  8. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I tr...

  9. Drug

    Sparteine

    go.drugbank.com/drugs/DB06727
    ApprovedWithdrawn

    Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents.

  10. Drug

    Adafosbuvir

    go.drugbank.com/drugs/DB14906
    Investigational

    Adafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335).